Medulloblastomas are aggressive tumors of primitive neuroectodermal origin. More than one third of patients diagnosed with medulloblastoma succumb to their disease within 5 years^[@R6]^ and surviving patients often have significant long-term adverse effects from current therapies. Identifying the underlying genetic events responsible for medulloblastomas can help guide the development of more effective therapies and refine the selection of currently available chemotherapy and radiotherapy. Recent efforts profiling transcriptional and DNA copy number changes in medulloblastoma have provided insights into the biological processes involved in these tumors and have underscored the molecular heterogeneity of this disease^[@R2]--[@R4]^. Based on these data, four broad subgroups have been established, known according to a consensus nomenclature as SHH, WNT, Group 3 and Group 4^[@R5]^.

Recently, Parsons et al. reported the first genome-scale sequencing of protein coding regions in medulloblastoma^[@R7]^. They identified alteration of genes encoding for histone modification proteins in 20% of cases, most notably *MLL2* and *MLL3*^[@R7]^. This initial survey was limited by a small discovery sample size (22 patients), lack of subtype-specific analysis, and use of Sanger sequencing technology insensitive to variants present at low allelic fraction. Here we survey coding somatic mutations at deeper coverage in a larger cohort of 92 medulloblastoma/normal pairs and assess these mutations in the context of specific molecular subtypes ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}).

In total, 1,908 mutations were detected within 1,671 of 18,863 genes sequenced to a median of 106X coverage ([Supplemental Table 2](#SD1){ref-type="supplementary-material"}). Confirmation of 20 candidate mutations in selected genes (*CTNNB1, DDX3X, SMARCA4, TP53,* and *CTDNEP1*) was performed by amplification of 48 exons using a microfluidic PCR device (Fluidigm) followed by single-molecule real-time sequencing (SMRT, Pacific Biosciences) ([Supplemental text](#SD1){ref-type="supplementary-material"}). Sequence data was unavailable for one *DDX3X* mutation due to poor PCR amplification from the sample. All remaining 19 mutations were confirmed by this orthogonal method (median 73 redundant subreads, range 3--287, [Supplemental Figure 1](#SD1){ref-type="supplementary-material"}).

A median of 16 somatic mutations (12 non-silent, 4 silent) per tumor was identified, corresponding to a mutation rate of 0.35 non-silent mutations per megabase of callable sequence, less than most adult solid tumors and consistent with results from Parsons et al^[@R7]^. Six of the twelve most frequently mutated tumors were from the oldest patients (16--31 years at diagnosis), consistent with increased mutation frequency in adult versus childhood medulloblastomas (p=7.7×10^−5^, Wilcoxon rank-sum test, [Supplemental Figure 2](#SD1){ref-type="supplementary-material"}).

To identify genes mutated at statistically significant frequencies across our cohort, we utilized the MutSig algorithm^[@R8]^ which takes into account gene size, sample-specific mutation rate, non-silent to silent mutation ratios, clustering within genes, and base conservation across species. In our cohort of 92 samples, we identified 12 significantly mutated genes (q \< 0.1, [Table 1](#T1){ref-type="table"}, [Supplemental Table 3](#SD1){ref-type="supplementary-material"}). Strikingly, these genes were not mutated in c5 (Group 3) and c4 (Group 4) tumors with extensive somatic copy number alteration ([Figure 1](#F1){ref-type="fig"}), suggesting these subtypes are driven primarily by structural variation, rather than base mutation. Not unexpectedly, *CTNNB1* (beta-catenin) and *PTCH1* were the two most significantly mutated genes (see [Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). Point mutations of *CTNNB1* in combination with loss of chromosome 6 were found in all WNT subgroup tumors and were concurrent with several other recurrently mutated genes, namely *CSNK2B*, *DDX3X, TP53* and *SMARCA4*. Mutations involving *PTCH1* occurred exclusively in SHH subgroup tumors and mutations of genes associated with the Hedgehog (Hh) pathway were also restricted to this subgroup (*p* \< 0.0001, Fisher's exact test). All but one of the tumors with *PTCH1* mutations had somatic loss of 9q, resulting in hemizygosity for the mutant allele. The remaining tumor had apparent copy neutral loss-of-heterozygosity of 9q22. Other somatic mutations of Hh pathway members include a splice site mutation in *SUFU,* an in-frame deletion in *WNT6,* and missense mutations in *GLI2, SMO, PRKACA, WNT2,* and *WNT2B.*

Two patients with SHH subgroup tumors had germline variants in *PTCH1*, one with somatic loss of 9q resulting in hemizygosity for a loss-of-function germline allele (MD-085, c.3030delC, p.Asn1011Thrfs\*38) and the other with a substitution previously reported in patients with holoprosencephaly (MD-286, p.T1052M^[@R9]^). Two additional cases (MD-097 and MD-335) had loss-of-function variants in *SUFU* (1 frameshift deletion and 1 nonsense) that began as heterozygotes in the germline and became hemizygous in the tumor, due to somatic loss of chromosome 10 in one case and copy neutral loss-of-heterozygosity in the other.

*MLL2* was also subject to recurrent inactivating mutations, consistent with findings by Parsons et al^[@R7]^ and providing further evidence for dysregulated histone modification in medulloblastoma. Indeed, six of the twelve most significantly mutated genes are involved in histone modification and/or related chromatin remodeling complexes (*MLL2, GPS2, KDM6A, BCOR, SMARCA4,* and *LDB1*; see [Table 1](#T1){ref-type="table"}). As a gene set, histone methyltransferases (HMTs) were enriched for somatic mutation with 21 tumors having apparent, predominantly loss-of-function, HMT mutations (q = 5.8×10^−9^; [Figure 2](#F2){ref-type="fig"}, [Supplemental Table 4](#SD1){ref-type="supplementary-material"}).

Subtype-specific MutSig analysis identified additional significant mutations of histone modifying genes, *MLL3* and *HDAC2,* in Group 4 tumors along with *KDM6A* mutations (q=0.039 and 0.066, see [Supplemental Table 3](#SD1){ref-type="supplementary-material"}). Mutations in KDM6A, interestingly, occurred exclusively in tumors with an i17q as the sole autosomal alteration (*p* = 0.0023, Fisher's exact test) with the one female case with *KDM6A* mutation also having loss of a chromosome X. Notably, the two 'i17q only' tumors without *KDM6A* mutations had other histone modifying enzymes mutated, namely *THUMPD3, ZMYM3* and *MLL3,* perhaps suggesting a distinct biology for tumors with this karyotype.

Mutations in several genes encoding components of the nuclear co-repressor (N-CoR) complex were observed at a statistically significant frequency: *BCOR* in 3 tumors, *GPS2* in 3 tumors, and *LDB1* in 2 tumors. *BCOR* mutations have recently been reported at high frequency in retinoblastoma^[@R10]^ and in 'copy-neutral' acute myelogenous leukemia^[@R11]^. *BCOR* is located on the X-chromosome and two hemizygous frameshift mutants were found in tumors from males (allele fractions 0.90 and 0.92). A third nonsense mutation was also found in a male but at low allelic fraction (0.12), suggesting a subclonal event. Two of three *BCOR* mutations occurred in SHH subgroup tumors. *LDB1* missense and nonsense mutations were found in two additional SHH tumors, both appearing hemizygous due to loss of 10q and complete chromosome 10 loss, respectively (allele fractions 0.81 and 0.78). Both *BCOR* and *LDB1* promote assembly of the repressive N-CoR complex^[@R12]^ and harbor apparent loss of function mutations. *GPS2*, which encodes a critical subunit of the N-CoR complex, a repressor of JNK/MAPK signaling through partnership with histone deacetylases^[@R2]^, was mutated in two Group 3 tumors. The *GPS2* mutations cluster within amino acids 53 -- 90, the domain critical for heterodimerization with *NCOR2* (SMRT) and interacting with a TBL1-NTD tetramer to assemble the N-CoR repression complex^[@R12]^. Finally, an additional nonsense mutation in *NCOR2* was identified in a single SHH subgroup tumor, underscoring the central role of N-CoR dysregulation in medulloblastoma development and particularly within the SHH subgroup.

Several genes encoding subunits of the SWI/SNF-like chromatin-remodeling complex were also mutated in our cohort, including significant recurrent mutations of *SMARCA4 (Brg/BAF190)*, which encodes a DNA helicase with ATPase activity^[@R13]^ and has been reported to be mutated in lung, ovarian, and pancreatic cancers^[@R14]^ as well as medulloblastoma^[@R15]^. In our cohort, *SMARCA4 (Brg/BAF190)* mutations clustered in helicase domains and occurred in three Group 3 tumors (significant within the c1 subtype, q=0.019), and one WNT tumor. In addition, mutations were found in the alternative ATPase subunit *SMARCD2 (Brm)* (missense at a highly conserved residue) and two other members of the SWI/SNF complex, *ARID1B (BAF250b)* (2 bp frameshift deletion) and *SMARCC2 (BAF170)* (splice site). These were all apparent loss-of-function mutations and occurred in SHH tumors. Thus, it appears that disruption of this complex is frequent across medulloblastomas.

Novel and hemizygous mutations were found in *CTDNEP1 (*previously known as *DULLARD),* a phosphatase with roles in *Xenopus* neural development through regulation of BMP receptors^[@R16]^, and as a direct regulator of LIPIN, an integral component of the mTOR complex^[@R17]^. *CTDNEP1* mutations were found in two Group 3 tumors (significant within the subtype, q=0.0087), a 2 bp frameshift deletion and a substitution disruptive of a splice site. Both tumors have i17q chromosomes resulting in loss of the wild type allele at 17p13.

Mutations in *DDX3X*, an ATP-dependent RNA helicase with functions in transcription, splicing, RNA transport and translation^[@R18]^, were found in seven tumors, including half of the WNT pathway tumors (*p* = 0.005, Fisher's exact test) and several SHH subgroup tumors. *DDX3X* mutations have recently been reported at low frequency in five other tumor types (Catalogue of Somatic Mutations in Cancer, COSMIC^[@R15]^) but the significance of these mutations for DDX3X function remains unclear. To understand the consequence of observed point mutations on DDX3X's physical structure, we mapped the mutations onto the previously reported crystal structure of DDX3X^[@R19]^ and its ortholog Vasa/DDX4^[@R20]^ ([Figure 3a](#F3){ref-type="fig"}; [Supplemental Figure 3](#SD1){ref-type="supplementary-material"}; [Supplemental table 5](#SD1){ref-type="supplementary-material"}). The mutations appear to cluster in two structural domains, a helicase ATP-binding domain (residues 211--403) and a helicase C-terminal domain (residues 414--575). The location of these mutations suggests that they may alter DDX3X-RNA interaction ([Figure 3a](#F3){ref-type="fig"}; [Supplementary table 5](#SD1){ref-type="supplementary-material"}).

As half of the beta-catenin mutated tumors contained concurrent *DDX3X* mutations, we investigated whether DDX3X could enhance beta-catenin's ability to transactivate a TCF4-luciferase reporter (TOPflash) and if DDX3X/beta-catenin co-expression had a measureable effect on cell viability/proliferation. In combination with wild-type beta-catenin, neither wild type nor mutant DDX3X alone significantly transactivated the TOPflash reporter. However, in combination with mutant beta-catenin (S33Y substitution), the majority of DDX3X point mutants in our cohort potentiated reporter activity ([Figure 3b](#F3){ref-type="fig"}; p \< 0.05). This potentiation was also apparent in cell viability assays in both HeLa (data not shown) and D425 medulloblastoma cell lines ([Figure 3c](#F3){ref-type="fig"}; p \< 0.05).

Given the apparent importance of *DDX3X* mutations in medulloblastoma, we searched the genes listed in the RNA Helicase Database^[@R30]^ for low frequency mutations in medulloblastoma. We found five tumors with mutations within RNA helicase or RNA binding domains of *DHX9*, *DHX32*, *DHX57*, *FANCM* and *SKIV2L* ([Figure 2](#F2){ref-type="fig"}, [Supplemental Table 6](#SD1){ref-type="supplementary-material"}). The missense mutations were at conserved residues and predicted to be deleterious by SIFT, AlignGVGD, and PolyPhen2. In addition, a frameshift insertion in *SETX* occurs upstream of, and likely disrupts, its RNA helicase domain. Overall, 15% of medulloblastomas appear to have some disruption of RNA helicase activity.

In summary, we report a next-generation sequencing analysis of medulloblastoma, the most common malignant brain tumor in children. Our results reveal mutations in several known pathways such as histone methylation (*MLL2* and others), sonic hedgehog (*PTCH1*, *SUFU*, and others) and Wnt (*CTNNB1* and others), and also mutations in novel genes including *DDX3X*, *BCOR*, *LDB1*, and *GPS2*. Our preliminary functional studies implicate DDX3X as a candidate component of pathogenic WNT/beta-catenin signaling. In a broader sense, *DDX3X* mutations have recently been reported in chronic lymphocytic leukemia^[@R21]^ and head and neck cancers^[@R22]^, both of which have subsets of tumors with dysregulated WNT signaling. Studies investigating whether mutant DDX3X functions complicit with beta-catenin in these contexts should provide additional insights into this multifaceted molecule and open potential avenues for novel therapies. Finally, the delineation of nuclear receptor co-repressor complex molecules as altered in medulloblastoma provides new insight into the pathogenesis of this deadly childhood disease.

Methods Summary {#S1}
===============

Informed consent was provided by families of medulloblastoma patients treated at Children's Hospital Boston, The Hospital for Sick Children Toronto and institutions contributing to the Children's Oncology Group/Cooperative Human Tissue Network, under approval and oversight by their respective Internal Review Boards. All tumors were obtained at the initial surgical resection and recurrent tumors were excluded from our analysis. Hematoxylin and eosin stained slides of tumor samples were pathologist reviewed to confirm the diagnosis of medulloblastoma, determine histological subtype when able, and assess tumor purity. DNA was isolated from tumor specimens and matched peripheral blood as previously described^[@R2]^. Exome sequencing of DNA from 92 tumor/normal pairs was performed using in-solution hybrid-capture of 193,094 exons from 18,863 miRNA- and protein-coding genes, followed by sequencing of 76 bp paired-end reads using Illumina sequencing-by-synthesis technology^[@R23]^. Reads were aligned to human genome build GRCh37^[@R24]^ using Burrows-Wheeler aligner^[@R25]^. The \~33 Mb target region was sequenced to 106X mean coverage in each sample (range 73 -- 234). Gene expression data and copy number profiles (derived from SNP microarrays or sequence data) were used to assign each tumor to a subgroup using published criteria^[@R2]^. Our cohort consisted of 6 WNT(c6), 23 SHH(c3), 33 Group 3(12 c1, 21 c5), and 30 Group 4(12 c2, 18 c4) tumors (see [Supplemental Table 1](#SD1){ref-type="supplementary-material"} for case annotations). Mutations were detected using muTect, annotated using Oncotator^[@R26]^, and manually reviewed using the Integrated Genomics Viewer (IGV)^[@R27]^. For validation, PCR on Access Array microfluidic chips (Fluidigm) was followed by single-molecule real-time sequencing (Pacific Biosciences) per manufacturer's instructions. Subreads were extracted and assigned to samples using manufacturer's and custom software, and aligned to the hg19 (GRCh37) build of the human reference genome sequence using BWA-SW^[@R25]^. Candidate mutations were confirmed by manual review using IGV^[@R27]^ ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}). See [Supplementary Information](#SD1){ref-type="supplementary-material"} and <http://www.broadinstitute.org/cancer/cga/> for complete descriptions of materials and methods.
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![Demographic characteristics, molecular subtypes and selected copy number alterations and somatic mutations across 92 medulloblastoma cases\
Data tracks describing 92 medulloblastoma cases. **Identifier:** Unique name used to denote each case. Identifiers also link samples to those analyzed by Cho et al. **Sex:** males in blue, females in pink. **Age:** years of age at diagnosis binned as infants, children, or adults. **Histology:** pathology review of primary tissue specimen. **Subtypes:** based on copy number profiles derived from sequence or microarray data. Consensus subtypes from Taylor et al. Cho et al subtypes as published. **Copy number alterations:** Selected copy number alterations used to assign tumors to subtypes. Losses are blue. Gains are red. **Somatic mutations:** Gene names (HUGO symbols) grouped by functional category. MutSig gene names are in bold. Missense mutations are black, nonsense/splice site/indel mutations are orange, silent mutations are purple, and germline variants are green.](nihms386385f1){#F1}

![Location of mutations in histone methyltransferases, RNA helicases, and N-CoR complex-associated genes\
Location of somatic mutations on linear protein domain models of genes from sets frequently mutated in medulloblastoma. All domain annotations are from UniProt and InterPro annotations. Diagrams were constructed using Domain Graph (DOG)^[@R28]^, version 2.0. **a.** Histone methyltransferase domains: red = SET, green = coiled-coil, blue = zinc-finger, and cyan=other. **b.** N-CoR complex-associated domains: purple = anti-parallel coiled-coil domains required for GPS2/NCOR2 (SMRT) interaction^[@R12]^, yellow = other interaction domains as labeled: SANT domains binds DNA; CoRNR domains binds nuclear receptors; ANK repeats mediate a diversity of protein-protein interactions, and LIM-binding domains bind a common protein structural motif. **c.** RNA helicase domains: cyan = helicase and helicase-associated (InterPro), red = RNA-binding and RNA polymerase sigma factor (InterPro), blue = ATP binding site, and green = DEAD or DExH box motif. See [Supplemental Table 1](#SD1){ref-type="supplementary-material"} for UniProt protein model identifiers.](nihms386385f2){#F2}

![Functional consequence of DDX3X point mutations\
**a,** Three-dimensional model of the two recA-like domains of human DDX3X in complex with single-stranded RNA and a Mg-ATP analog. Displayed are the residues mutated in the N-terminal recA-like domain (R276K, D354H, R376C) and C-terminal recA-like domain (D506Y, R528H, R534H, P568L). Coloring: DDX3X residues 166--405 (light blue); DDX3X residues 406--582 (dark blue); single-stranded RNA (cyan); Mg-ATP analog (magenta and green). Molecular graphics images were produced using the University of San Francisco Chimera package^[@R29]^ (<http://www.cgl.ucsf.edu/chimera>). **b**, Mutant DDX3X potentiates mutant beta-catenin transactivation of TOPflash promoter. Represented is relative luciferase activity in 293T cells co-transfected with TOPflash reporter, FOPflash control, and either wild type or mutant DDX3Xs in combination with wild type or mutant beta-catenin. One-dimensional model of DDX3X displayed about bar graphs to illustrates the position of the mutations. **c**, Cell viability assays of medulloblastoma D425 cells stably transduced with either wild type or mutant DDX3X lentivirus in combination with either wild type or mutant beta-catenin lentivirus.\
For b and c, error bars depict the standard deviation of the mean from 5 replicate experiments performed for each condition. Student's t-tests were performed to evaluate significance of differences in TOPflash intensity or cell proliferation value distributions as follows: increases with DDX3X alone vs. empty vector, increases with wtBetaCat vs. DDX3X alone, increases with mutBetaCat vs. DDX3X alone, and increases with mutBetaCat vs. wtBetaCat.](nihms386385f3){#F3}

###### 

Genes mutated at a statistically significant frequencyin 92 medulloblastomas

  Gene                 Description                                    Mutations   Patients   Unique sites   Silent   Missense   Indel or null   Double null   q
  -------------------- ---------------------------------------------- ----------- ---------- -------------- -------- ---------- --------------- ------------- ---------------
  *CTNNB1*             beta-catenin                                   6           6          4              0        6          0               0             \<1.8×10^−11^
  *PTCH1*              patched homolog 1(Drosophila)                  7           7          7              0        0          7               0             4.0×10^−9^
  *MLL2*               myeloid/lymphoid or mixed-lineage leukemia 2   10          8          10             0        2          4               4             4.0×10^−9^
  *DDX3X*              DEAD box polypeptide 3, X-linked               7           7          7              0        7          0               0             2.3×10^−8^
  *GPS2*               G protein pathway suppressor 2                 3           3          3              0        1          2               0             1.2×10^−4^
  *TP53*               tumor protein p53                              3           3          3              0        3          0               0             0.039
  *KDM6A*              UTX, lysine (K)-specific demethylase 6A        3           3          3              0        2          1               0             0.042
  *BCOR*               BCL6 co-repressor                              3           3          3              0        0          3               0             0.046
  *SMARCA4*            ATP-dependent helicase                         4           4          3              0        4          0               0             0.046
  *LDB1*               LIM domain binding 1                           2           2          2              0        1          1               0             0.047
  *CTDNEP1(DULLARD)*   CTD nuclear envelope phosphatase 1             2           2          2              0        0          2               0             0.047
  *CSNK2B*             casein kinase 2, beta polypeptide              2           2          2              0        2          0               0             0.071

**null** = nonsense, frameshift, or splice-site mutations; **Double null** = null mutations co-occurring in a single tumor; **q** = q-value, False Discovery Rate (Benjamini-Hochberg procedure). See [Supplemental Table 3](#SD1){ref-type="supplementary-material"} for further statistics and subtype analysis.
